Laquinimod-d5

Laquinimod-d5

• Product Name Alternative: ABR-215062-d5
• CAS Number: 1214267-09-0
• UNSPSC Description: Laquinimod-d5 (ABR-215062-d5) is deuterium labeled Laquinimod. Laquinimod (ABR-215062), an orally available carboxamide derivative, is a potent immunomodulator that prevents neurodegeneration and inflammation in the central nervous system. Laquinimod reduces astrocytic NF-κB activation to protect from Cuprizone-induced demyelination. Laquinimod has the potential for relapsing-remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases research[1].
• Target Antigen: Apoptosis; Isotope-Labeled Compounds; NF-κB
• Type: Isotope-Labeled Compounds
• Related Pathways: Apoptosis;NF-κB;Others
• Field of Research: Inflammation/Immunology
• Purity: 98.25
• Solubility: DMSO : 100 mg/mL (ultrasonic)
• Smiles: [2H]C1=C([2H])C([2H])=C(N(C(C2=C(O)C3=C(N(C)C2=O)C=CC=C3Cl)=O)CC)C([2H])=C1[2H]
• Molecular Weight: 361.83
• References & Citations: [1]Varrin-Doyer M, et al. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis. Exp Neurol. 2014 Dec;262 Pt A:66-71.
• Shipping Conditions: Room Temperature
• Storage Conditions: -20°C, 3 years; 4°C, 2 years (Powder)
• Clinical Information: No Development Reported